The First-Ever Transplantation with a Donor Heart Transported Across the Atlantic Ocean - Made Possible by the use of XVIVO’s Heart Technology - Seite 2

Andreas Wallinder, CMO at XVIVO, continues, "We are extremely proud of our heart technology that is now under investigation in several clinical trials. Together with the recently reported successful outcomes from an Australian/New Zealand trial, the PEGASE study may be leading the way in a transformation of heart transplant practices as we know it today. Improved patient outcomes and bridging of geographical distances will allow for more and safer transplantations. This will also mean that the wish and precious gift of the donor can be respected as more organs are utilized."

"I'd like to express my sincere congratulations to Professor Lebreton and his team. It makes me very proud that XVIVO's heart technology has once again broken records. The success achieved in this instance, where distance and transport time are no longer limiting factors, demonstrates that this technology has the potential to change the paradigm of heart preservation. XVIVO has now taken another significant step toward realizing our vision that ‘nobody should die waiting for a new organ'", says Christoffer Rosenblad, CEO XVIVO.

February 29, 2024
Gothenburg
Christoffer Rosenblad, CEO
XVIVO Perfusion AB (publ)

[1] https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)002 ...

For further information, please contact:

Christoffer Rosenblad, CEO, [phone], e-mail: [e-mail]
Kristoffer Nordström, CFO, [phone], e-mail: [e-mail]

About Us

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.

Attachments

The first-ever transplantation with a donor heart transported across the Atlantic Ocean - made possible by the use of XVIVO's heart technology

SOURCE: XVIVO Perfusion AB

View the original press release on accesswire.com


The Xvivo Perfusion Stock at the time of publication of the news with a raise of +0,40 % to 257SEK on London stock exchange (29. Februar 2024, 11:42 Uhr).